Health Winners & Losers: AstraZeneca
After an early rally, health stocks closed Wednesday's trading session down.
In business news, Sigma-Aldrich (SIAL) and Sangamo BioSciences (SGMO) announced a research and license agreement with Roche wherein Roche will receive non-exclusive worldwide rights for the use of its zinc finger nuclease technology for cell lines and transgenic (or genetically modified) animals. Specific financial terms were not disclosed. Sangamo shares rose 15 cents, or 1.4%, to $10.82.
Wyeth (WYE) said on Wednesday that a U.S. District Court in Arkansas granted its motion for judgment regarding law on the punitive damages award in hormone therapy case Donna Scroggin v. Wyeth. The decision overturns punitive damages awarded by the Little Rock jury last year of $19.3 million and also clears the way for the company to appeal compensatory damages of $2.75 million, according to Wyeth. The new ruling also vacates the $7.76 million in punitive damages award against co-defendant Upjohn.
Wyeth shares traded down 93 cents, or 1.9%, at $48.55.Elsewhere, AstraZeneca (AZN)-owned MedImmune won a federal contract, valued at a maximum of $28.4 million, to provide military agencies with its intranasal spray flu vaccine, FluMist. The vaccines, which are being stockpiled in case of an epidemic will last through June of next year. AstraZeneca's shares traded up 58 cents, or 1.2%, to $47.80. Meanwhile, Bernstein analyst Tim Anderson said in a note to investors that Schering-Plough (SGP) and Merck (MRK) may release data from the SEAS trial on controversial cholesterol drug Vytorin at the American Heart Association annual meeting in November. Although, he notes, neither company has yet said when the data will come out.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV